Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0098858820933499 http://scihub22266oqcxt.onion/10.1177/0098858820933499 32659196!ä!32659196 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32659196.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Am+J+Law+Med 2020 ; 46 (2-3): 275-296 Nephropedia Template TP {{tp|p=32659196|t=2020. Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influence |pdf=|usr=}}{{32659196}} gab.com Text Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influence JO: Am J Law Med http://www.kidney.de/pget.php?&tw=1&pmid=32659196 #FOAvip Corporate influence is one of the most pressing issues in public health. It cuts across many of our most intractable problems-from obesity to the opioid epidemic. Companies develop close relationships with public health agencies, research universities, academic medical centers, professional societies, and patient advocacy organizations-often funding medical research and public health interventions intended to address the very challenges these corporations are creating or exacerbating. How we view relationships with industry, including how these relationships are framed in ethical discourse, shapes our legal and policy responses to them. In recent years, fueled in part by the opioid epidemic, the ethical framing of industry relationships has begun to evolve in significant ways. But legal and policy responses have not yet caught up. In this article, I develop a temporal account of corporate influence, and legal and policy responses to corporate influence. This account clarifies the limitations and adverse effects of conflicts of interest disclosure, especially when implemented as the sole legal or policy response. Disclosure can illuminate corporate influence-but policymakers cannot and should not rely on disclosure to eliminate corporate influence or its effects. Nor should we allow disclosure to crowd out structural and systemic responses to corporate influence-including sequestration of and separation from private-sector entities. Twit Text FOAVip Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influence ????Am J Law Med http://www.kidney.de/pget.php?&tw=1&pmid=32659196 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32659196 #FOAvip English Wikipedia <ref>{{Cite pmid|32659196}}</ref> Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influence #MMPMID32659196 Marks JH Am J Law Med 2020[May]; 46 (2-3): 275-296 PMID32659196show ga Corporate influence is one of the most pressing issues in public health. It cuts across many of our most intractable problems-from obesity to the opioid epidemic. Companies develop close relationships with public health agencies, research universities, academic medical centers, professional societies, and patient advocacy organizations-often funding medical research and public health interventions intended to address the very challenges these corporations are creating or exacerbating. How we view relationships with industry, including how these relationships are framed in ethical discourse, shapes our legal and policy responses to them. In recent years, fueled in part by the opioid epidemic, the ethical framing of industry relationships has begun to evolve in significant ways. But legal and policy responses have not yet caught up. In this article, I develop a temporal account of corporate influence, and legal and policy responses to corporate influence. This account clarifies the limitations and adverse effects of conflicts of interest disclosure, especially when implemented as the sole legal or policy response. Disclosure can illuminate corporate influence-but policymakers cannot and should not rely on disclosure to eliminate corporate influence or its effects. Nor should we allow disclosure to crowd out structural and systemic responses to corporate influence-including sequestration of and separation from private-sector entities. |*Ethics, Business[MESH] |*Policy Making[MESH] |Biomedical Research/*legislation & jurisprudence[MESH] |Conflict of Interest[MESH] |Disclosure/*legislation & jurisprudence[MESH] |Humans[MESH] |Public Health/*legislation & jurisprudence[MESH] |Research Support as Topic/legislation & jurisprudence[MESH]Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influ(epmc).pdf DeepDyve Pubget Overpricing